Recombinant Human KGF-2/FGF-10
Fibroblast growth factor 10 belongs to the fibroblast growth factor (FGF) family which is involved in a variety of biological processes such as embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. Like most other FGF family members, FGF-10 also has a heparin-binding domain and it plays an important role in the regulation of embryonic development, cell proliferation and cell differentiation. In addition, FGF-10 may play a role in wound healing and is required for normal branching morphogenesis. Recombinant human FGF-10 contains a 208 amino acids and it shares 92 % and 95 % amino acid sequence identity with murine and rat FGF-10. Defects in FGF-10 are the cause of autosomal dominant aplasia of lacrimal and salivary glands and lacrimo-auriculo-dento-digital syndrome.
Reference:
1. Emoto H, Tagashira S, Mattei MG, et al. 1997. J Biol Chem. 272:23191-4.
2. Tagashira S, Harada H, Katsumata T, et al. 1997. Gene. 197:399-404.
3. Carninci P, Kasukawa T, Katayama S, et al. 2005. Science. 309:1559-63.
4. Igarashi M, Finch PW, Aaronson SA. 1998. J Biol Chem. 273:13230-5.
5. Entesarian M, Matsson H, Klar J, et al. 2005. Nat Genet. 37:125-7.
|
Gene ID |
2255 |
|
Accession # |
O15520 |
|
Alternate Names |
FGF10, FGF-10, fibroblast growth factor 10, Keratinocyte growth factor 2, KGF2, KGF-2 |
|
Source |
Escherichia coli. |
|
M.Wt |
Approximately 19.1 kDa, a single, non-glycosylated polypeptide chain containing 169 amino acids. |
|
AA Sequence |
LGQDMVSPEA TNSSSSSFSS PSSAGRHVRS YNHLQGDVRW RKLFSFTKYF LKIEKNGKVS GTKKENCPYS ILEITSVEIG VVAVKAINSN YYLAMNKKGK LYGSKEFNND CKLKERIEEN GYNTYASFNW QHNGRQMYVA LNGKGAPRRG QKTRRKNTSA HFLPMVVHS |
|
Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
|
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70 °C as supplied. - 1 month, 2 to 8 °C under sterile conditions after reconstitution. - 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
|
Formulation |
Lyophilized from a 0.2 µm filtered concentrated solution in 2 × PBS, pH 7.4. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
|
Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by thymidine uptake assay using FGF-receptors transfected BaF3 cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 106 IU/mg. |
|
Shipping Condition |
Gel pack. |
|
Handling |
Centrifuge the vial prior to opening. |
|
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 97 % by SDS-PAGE and HPLC analyses.
- Datasheet
Endotoxin: Less than 1 EU/µg of rHuKGF-2/FGF-10 as determined by LAL method.